By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Genomic Health, Inc. 

301 Penobscot Drive

Redwood City  California  94063  U.S.A.
Phone: 650-556-9300 Fax: 650-556-1132


Genomic Health, Inc. (NASDAQ: GHDX) is the world’s leading provider of genomic-based diagnostic tests that address the overtreatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results throughout the cancer patient’s journey, from screening and surveillance, to diagnosis, to treatment selection and monitoring. Genomic Health’s lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with stage II and stage III disease, and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of June 30, 2013, more than 19,000 physicians in over 70 countries had ordered more than 375,000 Oncotype DX tests. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.

For more information, please visit,
and follow the company on Twitter: @GenomicHealth. To learn more about Oncotype DX tests, visit:
, and

Key Statistics

Ownership: Public

Web Site: Genomic Health, Inc.
Symbol: GHDX

Medical Device

Company News
Genomic Health, Inc. (GHDX) Release: The Oncotype DX® Test And Precision Oncology: New Data Presented At ESMO Further Demonstrate Genomic Health’s Successful Approach To Understanding Tumor Biology 9/29/2014 12:57:17 PM
Genomic Health, Inc. (GHDX) Announces Positive Results From Latest Clinical Validation Study Of Oncotype DX® As Predictor Of Near- And Long-Term Outcomes In Racially Diverse Group Of Prostate Cancer Patients 9/29/2014 9:46:34 AM
Genomic Health, Inc. (GHDX) Announces Oral Presentation Of Positive Results From Second Large, Independent Clinical Validation Study Of Oncotype DX® In DCIS Breast Cancer At 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) 9/26/2014 7:42:57 AM
Genomic Health, Inc. (GHDX) Release: New Survey Reveals Alarming Lack Of Understanding Of Prostate Cancer, Inspires "Your Prostate Your Decision" Education Campaign With Baseball Hall-Of-Famer Joe Torre 9/24/2014 8:23:01 AM
Genomic Health, Inc. (GHDX) Announces Publication Of Colon Cancer Cost-Effectiveness Study In Pharmacoeconomics 9/12/2014 9:50:17 AM
Genomic Health, Inc. (GHDX) Announces Presentation Of Positive Results From Latest Prostate Cancer Clinical Validation Study At The European Society For Medical Oncology (ESMO) 2014 Congress 9/9/2014 8:09:28 AM
New England Biolabs, Inc.® Introduces New Ribosomal RNA Depletion Technology From Genomic Health, Inc. (GHDX) 8/19/2014 8:16:56 AM
Genomic Health, Inc. (GHDX) To Present At The Canaccord Genuity 34th Annual Growth Conference 8/8/2014 8:54:23 AM
Genomic Health, Inc. (GHDX) Announces Second Quarter 2014 Financial Results And Business Progress 8/8/2014 8:01:57 AM
Genomic Health, Inc. (GHDX) Announces Positive Topline Results Of Additional, Large Independent Validation Study Of Oncotype DX® Prostate Cancer Test With Multiple Clinical Endpoints 8/6/2014 8:30:29 AM